1. Show article details.

    BRIEF-Mesa Labs Reports Q3 Loss Per Share Of $1.06

    Reuters – 8:11 AM ET 02/10/2020

    Mesa Laboratories Inc (MLAB): * MESA LABS REPORTS THIRD QUARTER RESULTS. * Q3 LOSS PER SHARE $1.06. * QUARTERLY ADJUSTED OPERATING INCOME PER SHARE $0.62. * QUARTERLY REVENUES $31.66 MILLION VERSUS $26.7 MILLION. * Q3 EARNINGS PER SHARE VIEW $1.00, REVENUE VIEW $31.3 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  2. Show article details.

    Mesa Labs Reports Third Quarter Results

    GlobeNewswire – 8:00 AM ET 02/10/2020

    Mesa Laboratories, Inc. (MLAB) today reported third quarter results for the three months ended December 31, 2019. Financial Results In comparison to the same quarter in the prior year, third quarter revenues increased 19% to $31,655, operating income decreased 356% to $ and net income decreased 640% to $ or $ per diluted share of common stock.

  3. Show article details.

    MESA LABS DECLARES QUARTERLY DIVIDEND

    GlobeNewswire – 7:00 PM ET 01/09/2020

     Mesa Laboratories, Inc. (MLAB) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. About Mesa Laboratories, Inc. Mesa is a global technology innovator committed to solving some of the most critical quality control challenges in the pharmaceutical, healthcare, industrial safety, environmental and food and beverage industries.

  4. Show article details.

    VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

    PR Newswire – 8:30 AM ET 12/05/2019

    AUSTIN, Texas, Dec. 5, 2019  VolitionRx Limited (VNRX) today announced that it was awarded $820,000 and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (MLAB) was awarded $230,000 each in the form of a non-repayable Eurostars cash grant.

  5. Show article details.

    Mesa Labs Reports Record Second Quarter Revenues and Adjusted Operating Income

    GlobeNewswire – 8:00 AM ET 11/06/2019

    Mesa Laboratories, Inc. (MLAB) today reported record second quarter revenues and adjusted operating income1 for the three months ended September 30, 2019. Financial HighlightsIn comparison to the same quarter in the prior year, second quarter revenues increased 3% to $25.5M, operating income increased 303% to $4.6M and net income increased 208% to $3.1M or $0.71 per diluted share of common stock.

  6. Show article details.

    Mesa Labs Acquires Gyros Protein Technologies

    GlobeNewswire – 8:55 PM ET 10/31/2019

     Mesa Laboratories, Inc. (MLAB), a diversified supplier of quality control instruments and consumables to highly regulated markets today announced the acquisition of Gyros Protein Technologies Holding AB. The acquisition price for GPT consisted of cash consideration of $180 million, subject to purchase price adjustments.

  7. Show article details.

    MESA LABS DECLARES QUARTERLY DIVIDEND

    GlobeNewswire – 5:00 PM ET 10/01/2019

    Mesa Laboratories, Inc. (MLAB) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. About Mesa Laboratories, Inc. (MLAB)          Mesa is a global technology innovator committed to solving some of the most critical quality control challenges in the pharmaceutical, healthcare, industrial safety, environmental and food and beverage industries.

Page:

Today's and Upcoming Events

  • Feb
    27

    MLAB ex-Dividend for $0.16 on 02/27/2020

    • Announce Date: 01/10/2020
    • Record Date: 02/28/2020
    • Pay Date: 03/16/2020

Past Events (last 90 days)

  • Feb
    10

    MLAB announced Q3 earnings.

  • Nov
    27

    MLAB ex-Dividend for $0.16 on 11/27/2019

    • Announce Date: 10/01/2019
    • Record Date: 11/29/2019
    • Pay Date: 12/16/2019
Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.